Ongoing clinical trials are investigating the use of various PD-1 inhibitors/modulators [nivolumab (105), atezolizumab (106), and pembrolizumab (107)] in combination with concurrent chemoradiation therapy (CCRT) for the management of advanced and recurrent cervical cancers. Here, PDCD1 is linked to cervical carcinoma.